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M
icroRNAs (miRs) are small single-
stranded noncoding RNAs that
target speciﬁc mRNAs for transla-
tional repression or degradation and that
have been implicated as key regulators in
numerous biological processes.15 Altered
miR expression has been reported in a
variety of disease states. With respect to
cancer, loss of miRs that exert tumor sup-
pressor functions can lead to malignant
transformation and cancer progression,
whereas overexpression of miRs that have
oncogenic properties can promote tumor
progression, invasion and metastasis.3,69
While not regulating gene expression
directly, a single miR can lead to alter-
ations in the expression of dozens or even
hundreds of genes and proteins, thereby
coordinately modulating a variety of cellular
functions.13,8
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ABSTRACT MicroRNAs are short noncoding RNAs consisting of 1825 nucleotides that
target speciﬁc mRNA moieties for translational repression or degradation, thereby modulating
numerous biological processes. Although microRNAs have the ability to behave like oncogenes or
tumor suppressors in a cell-autonomous manner, their exact roles following release into the
circulation are only now being unraveled and it is important to establish sensitive assays to
measure their levels in diﬀerent compartments in the circulation. Here, an ultrasensitive localized
surface plasmon resonance (LSPR)-based microRNA sensor with single nucleotide speciﬁcity was
developed using chemically synthesized gold nanoprisms attached onto a solid substrate with
unprecedented long-term stability and reversibility. The sensor was used to speciﬁcally detect
microRNA-10b at the attomolar (1018 M) concentration in pancreatic cancer cell lines, derived
tissue culture media, human plasma, and media and plasma exosomes. In addition, for the ﬁrst
time, our label-free and nondestructive sensing technique was used to quantify microRNA-10b in highly puriﬁed exosomes isolated from patients with
pancreatic cancer or chronic pancreatitis, and from normal controls. We show that microRNA-10b levels were signiﬁcantly higher in plasma-derived exosomes
from pancreatic ductal adenocarcinoma patients when compared with patients with chronic pancreatitis or normal controls. Our ﬁndings suggest that this
unique technique can be used to design novel diagnostic strategies for pancreatic and other cancers based on the direct quantitative measurement of plasma
and exosome microRNAs, and can be readily extended to other diseases with identiﬁable microRNA signatures.
KEYWORDS: gold nanoprisms . LSPR-based sensor . microRNAs . cancer biomarkers . exosomes . pancreatic cancer .
chronic pancreatitis . cancer diagnosis
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Pancreatic ductal adenocarcinoma (PDAC) is a deadly
cancer with an overall 5-year survival rate of 7%.10 The
vast majority of PDAC patients (∼80%) present with
advanced disease that precludes surgical resection,
yet resection is the only hope for a cure. Major causes
for this late presentation of the cancer include its hidden
location within the abdomen, its ability to remain
symptom-free for many years prior to clinical presenta-
tion, diﬃculties inherent in imaging small pancreatic
lesions, and the absence of PDAC-speciﬁc circulat-
ing biomarkers when the cancer is still small, symptom
free, and nonmetastatic. Therefore, the identiﬁcation of
speciﬁc biomarkers in the circulation that will allow for
the early PDAC diagnosis constitutes an urgent unmet
need for this cancer.
It has been demonstrated that miR-10b is over-
expressed in pancreatic cancer cells (PCCs) in PDAC;11
that this overexpression is associated with shorter time
to metastasis following therapy and decreased patient
survival;12 and that the plasma levels of miR-10b, miR-
30c, miR-132, miR-155, and miR-212 levels can help
diﬀerentiate between PDAC and individuals without
pancreatic pathology.13 In general, miRs can be re-
leased by cancer cells through four diﬀerent mechan-
isms. Thus, miRs can be released bound to the Ago2
protein or to high-density lipoprotein (HDL) particles,
or carried as cargo within exosomes or microvescicles,
as shown in Scheme 1.14,15 It is believed that PCCs
release a preponderance of exosomes over any
other type of vesicles.16 Exosomes are tiny vesicles
(∼40140 nm in diameter) delineated by a lipid bilayer
each of which carries a cargo of proteins, DNA, mRNAs,
and miRNAs.1720 They have the ability to participate
in intercellular communications between cells and
their microenvironments, resulting in the modulation
of various cellular processes.17,21 It is not known, how-
ever, whether miR-10b can be released by PCCs into
themedium or circulation, andwhethermiR-10b levels
in the exosome compartment can diﬀerentiate be-
tween PDAC, chronic pancreatitis (CP), and individuals
without PDAC pathology.
To quantify miR-10b release by PCCs into the circu-
lation and to determine whether this release occurs via
exosomal and/or nonexosomal compartments, it will
likely be necessary to determine miR concentrations
in PCC-derived conditioned media at subattomolar
concentrations. In this regard, it would be extremely
useful to develop highly sensitive, label-free, nondes-
tructive, and highly speciﬁc methods for the detection
and quantiﬁcation ofmiR-10b directly in culturemedia,
patient plasma and exosomes in both compartments.
By contrast, current miR detection/quantiﬁcation meth-
ods such as microarray-, real-time quantitative PCR-,
electrochemical-, ﬂuorescence-, microring resonator-,
and nanopore-based techniques2232 are either semi-
quantitative, require ampliﬁcation and labeling, or fail to
work directly in biological ﬂuids.
Here, we report a highly speciﬁc, ultrasensitive,
and regenerative localized surface plasmon resonance
(LSPR)-based miR-10b sensing approach that over-
comes the above limitations. The solid-state LSPR-based
sensors were developed using glass substrate-bound
gold nanoprisms functionalized with complementary
oligonucleotides (Figure 1). Importantly, our sensor
was able to distinguish between miR-10b and miR-10a,
indicating that it provides for single nucleotide speciﬁ-
city. We also demonstrate the usefulness of miR quanti-
ﬁcation by LSPR-based technique in cultured PCCs
(AsPC-1, BxPC-3, and PANC-1), derived conditioned
media, and exosomes. The attomolar (aM) limit of
detection (LOD), at least 1000-fold lower than current
label-free methods,2224,26,28,29,31,32 of our LSPR-
based sensor allowedus to readily diﬀerentiatebetween
miR-10b levels in PDAC and CP patients, and normal
controls in plasma, exosomes, and post-ultracentrifuga-
tion supernatants. We propose that our label-free and
ultrasensitive assay, which detects very small increases
in miR-10b levels, could allow for early stage PDAC
detection and permit monitoring for PDAC recurrence
following therapy or resection.
RESULTS AND DISCUSSION
Fabrication of miR-10b Sensor and Characterization of Long-
Term Stability and Selectivity. Solid-state, label-free bio-
sensors have been fabricated3343 using the unique
LSPR-properties of metallic nanostructure.3638,44 How-
ever, in most cases, the sensors failed to work in
biological samples because various constituents pre-
sents in plasma and serum react with the sensors.
Recently, we reported the first solid-state fabrication
and characterization of miR-21 andmiR-10b sensors uti-
lizing LSPR properties of anisotropically shaped metallic
nanostructures with LOD ∼ 35 femtomolar (fM).45 Our
sensor could accurately quantify miR-21 in plasma from
patients with PDAC. The LSPR-based sensor fabrica-
tion involved two steps: (i) covalent attachment of
Scheme 1. Cellular pathways for release of microRNAs into
the circulation. Exosomes are formed within multivesicular
bodies (MVBs) and released into the circulation when
the MVB-limiting membrane interacts with the plasma
membrane.14,15
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chemically synthesized ∼40 nm edge-length gold
nanoprisms onto a silanized glass substrate; (ii) functio-
nalization of the nanoprism surfacewith 1:1mole ratio of
single-stranded DNAs (HS-C6-ssDNA) and poly(ethylene
glycol)6-thiols (PEG6-SH) spacer.
The LSPR-based sensingmechanism involves direct
hybridization between -S-C6-ssDNA and target miRs
(Figure 1) to form DNA duplex, which increases the
refractive index in local dielectric environment of
the nanoprisms and inﬂuences the LSPR dipole peak
(λLSPR) by shifting it to higher wavelengths. LOD can
be calculated from the total shift (ΔλLSPR) versus the
concentration of miRs using the empirical formula
described below. The data were correlated with the
widely used quantitative reverse-transcriptase-PCR
(qRT-PCR) method, both techniques yielding results
which were in excellent agreement. To achieve
our goal of obtaining an aM LOD, we adopted the
similar LSPR-based sensor fabrication technique
as described previously45 while investigating the
eﬀects of the nanoprism's edge-length on sensing
eﬃciency and LOD. The detailed procedure for
sensor fabrication is provided in the Supporting
Information .
Chemically synthesized gold nanoprisms, which
displayed λLSPR at 750, 800, and 820 nm in acetonitrile
(Figure S1) with average edge-lengths of 34, 42, and
47 nm, respectively, as determined from scanning
electron microscopy images (Figure 2AC), were used
in sensor fabrication. Figure 2E illustrates the change
of λLSPR position during the functionalization of gold
nanoprisms with 42 nm of average edge-length, which
were attached onto silanized glass. The red-shift of the
λLSPR position suggested an increase in local refractive
index3638,41,42,4649 from the attachment ofmolecular
species on the gold nanoprism's surface. The LODs of
miR-10b detection for 34, 42, and 47 nm edge-length
nanoprisms were calculated in human plasma and
were found to be 47.5, 0.091, and 0.083 fM, respectively
(see Figure 2F and Table S2). The LODs were calculated
by measuring the ΔλLSPR for the blank sample
(mixed -S-PEG6:-SC6-ssDNA-10b functionalized gold
nanoprisms attached onto silanized glass substrate)
and then calculating the Z (mean þ 3σ) value. The
Z value was then converted into the relative concentra-
tion using the calibration curve. The data suggest that
as the edge-lengths of the nanoprisms increase, their
sensing volume40,43,5052 also increases, thereby enhanc-
ing the LSPR sensitivity of the nanoprisms. This result
is also in agreement with the literature where largest
gold nanoparticles demonstrated highest LSPR-based
sensing ability toward the detection of proteins.35
Thus, a minute change in a nanoprism's local dielectric
environment due to analyte absorption can dramati-
cally inﬂuence the LSPR properties and λLSPR position.
It is important to mention that the ﬁnal λLSPR values
after -ssDNA-miR-10b and miR-10b hybridization were
determined in PBS buﬀer (wet LSPR-based sensors)
instead of air in order to avoid the eﬀects of bulk
refractive index caused by the surrounding media
(water). Moreover, our lowest LOD of 83 aM was more
than 106-, 104-, and 103-fold lower than the label-free
ﬂuorescent-,23,53 microring resonator-,26,29 and nano-
pore-based31,32 miR sensors, respectively. To the best
of our knowledge, this is the lowest LOD reported in the
literature for LSPR-based sensors for detecting any-type
of biomolecules in complex physiological media such
as human plasma. This label-free technique has also
proven to bemore sensitive thanmetal nanoparticle-
based surface-enhanced Raman scattering sensing
(LOD = 1.5 fM) of mouse pancreatic tumor.54 At
higher concentrations we observed large error bars
(Figure 2F), which points to limitations of our sensing
platform. However, the concentration range (10 nM
to 10 pM) at which we observed this enhanced
variability is well above the concentration range of
the values seen in PDAC and CP patients as shown
later in this article.
Figure 1. Schematic representation of the fabrication of the mixed -S-PEG6:-SC6-ssDNA-functionalized gold nanoprisms to
prepare LSPR-based sensing platform for miR-10b detection in various biological compartments. Three diﬀerent edge
lengths gold nanoprisms (34, 42, and 47 nm) were synthesized via our previously published chemical reduction method and
then attached onto silanized glass surface.45 All the surface modiﬁcations were performed in PBS buﬀer (pH = 7.4) under
normal laboratory conditions. Detailed procedure for sensor fabrication and RNA isolation are provided in the Materials and
Methods. The ﬁgure is not to scale.
A
RTIC
LE
JOSHI ET AL. VOL. 9 ’ NO. 11 ’ 11075–11089 ’ 2015
www.acsnano.org
11078
The best LOD of our LSPR-based sensors were fabri-
cated with 47 nm edge-length gold nanoprisms and
demonstrated an LOD of 83.2 aM. However, functiona-
lization of gold nanoprisms with 1:1 mole ratio of
HS-C6-ssDNA-10b and PEG6-SH shifted the λLSPR peak
to ∼863 nm. Upon further incubation with miR-10b,
the λLSPR position shifted even closer to the near-
infrared region, where other biological constituents
present in the media and a water peak could interfere
with reading the λLSPR of nanoprisms and potentially
cause misleading LOD values. Therefore, we chose to
use 42 nm edge length nanoprisms (λLSPR =∼800 nm)
(LOD = 91 aM) for LSPR-based sensor fabrication
for further studies as described below. The LOD was
slightly lower (32.6 aM) and exhibited less background
signal in the LSPR peak shift (ΔλLSPR) in PBS buﬀer than
that in human plasma (91 aM) (Table S3). Our data are
in agreement with the ﬁnding of a higher LSPR-based
detection of streptavidin in serum by comparison with
PBS buﬀer.55 Therefore, it is possible that diﬀerences
in ionic strength or salt concentrations between PBS
buﬀer and plasma, in conjunction with some non-
speciﬁc adsorption of plasma protein could occur on
the silanized glass substrate within the sensing volume
of gold nanoprisms, which could explain the slight
deferences in assay sensitivity between PBS buﬀer and
human plasma.
The unprecedented sensitivity of our LSPR-based
sensor fabricated with gold nanoprisms is the result
of a combination of several important structural param-
eters. First, the atomically ﬂat surface of the nano-
prisms enables homogeneous packing between -ssDNA
Figure 2. Scanning electron microscopy (SEM) images of three diﬀerent edge-length gold nanoprisms were used for LSPR-
basedmiR-10b sensors fabrication: (A) 34nm, (B) 42 nm, and (C) 47 nm. Scale bars: 100nm. (D) Atomic forcemicroscopy image
of (on the average) 42 nm edge length gold nanoprisms. (E) Changes in the LSPR dipole peak (λLSPR) position of averagely
42 nm edge length gold nanoprisms before (black) and after (red) functionalization with mixed HS-PEG6:HSC6-ssDNA-10b.
The sensing platform was then rinsed with PBS buﬀer and incubated with 10 nM of miR-10b solution in human plasma;
then, rinsed with PBS buﬀer and dipole peak position (blue) was determined. (F) Average λLSPR shift (ΔλLSPR) of the sensing
platforms, which were prepared with three diﬀerent edge lengths nanoprisms, 34 nm (purple triangles), 42 nm
(red diamonds), and 47 nm (blue dots) as a function of miR-10b concentration. All extinction spectra were measured
in PBS buﬀer to determine the ΔλLSPR. The green bar represents three times the standard deviation (σ) of the blank (mixed
HS-PEG6:HSC6-ssDNA-10b functionalized gold nanoprisms attached onto silanized glass substrate). Inasmuch as log scale
is commonly used in the LSPR biosensing literature,35,40,46 in order to investigate nonspeciﬁc absorption at a lower
concentration range, concentrations were plotted on the axis in log scale.
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and PEG spacers, which allows eﬃcient DNA/RNA
duplex formation. Second, that double-strand DNA that
forms between -ssDNA/RNA displays a high charge
density and the change in polarization could signiﬁ-
cantly alter the local refractive index.56 Third, the strong
electromagnetic ﬁeld enhancement occurring at the
sharp tips of the nanoprisms43,57,58 would modulate
the nanoprism's LSPRproperties following small changes
in their local dielectric environment. Fourth, there could
be a long-range charge transfer mediated by double-
strand DNA, which would result in alterations in the elec-
tron density around the nanoprisms that could inﬂuence
the LSPRproperties. Fifth, the large sensing volumecould
detectminute change in the local dielectric environment
due to the adsorption of analytes.
We next investigated the regeneration ability our
LSPR-based sensor by hybridization and dehybridiza-
tion of miR-10b for at least 5 times over a 5-day period,
using the same LSPR-based sensor while monitoring
the λLSPR shift, which was nearly identical each time
before and after hybridization and dehybridization of
miR-10b. Therefore, our sensor is highly regenerative.
Furthermore, the inert character of gold nanostruc-
tures toward biological constituents present in human
plasma, as well as the strong goldsulfur bond which
holds tightly the -ssDNA-10b, likely confers long-term
stability to the sensors, which will enhance their po-
tential for development into point of care diagnostic
tools.We also determined that our LSPR-based sensors,
which contain the speciﬁc antisense -ss-DNA-10b at-
tached to the gold nanoprisms, are extremely speciﬁc
toward their target miRs. The experimental data con-
cerning regeneration and speciﬁcity of our sensors are
provided in the Supporting Information (Figures S2
and S3) In our speciﬁcity study, 1.7 nm ΔλLSPR was
observed when the LSPR-based sensor was incubated
in a solution containing four diﬀerentmiRs (10 nM/miR;
40 nM total concentration). This value is very low in
comparison to the 12.8 nm ΔλLSPR value observed
upon incubation of our sensor with10 nM miR-10b.
Therefore, we believe that a ΔλLSPR of 1.7 nm could
be due to a combination of instrumental noise
and/or negligible nonspeciﬁc adsorption of miRs onto
silanized glass substrate within the sensing volume
of the gold nanoprisms, which was determined by us
to be ∼25 nm for 42 nm gold nanoprisms.59 Impor-
tantly, at the lower concentration range (100 fM and
100 aM), theΔλLSPR values were same as blank samples
(data not shown).
Mir-10b has an identical seed sequencewithmiR-10a,
but their mature forms diﬀer at a single nucleotide.
Thus, miR-10b and miR-10a contain nucleic acid A
and U at the 12th position from 50 end, respectively.
Moreover, the genes encoding miR-10b and 10a are
located on chromosomes 2 and 17, respectively, and
The Cancer GenomeAtlas (TCGA) data indicate that 4%
of PDACs exhibit miR-10b ampliﬁcation and 4% exhibit
miR-10a ampliﬁcation, but these cases are not over-
lapping. Therefore, we next investigated the ability
of our LSPR-based sensor to distinguish between
miR-10b and miR-10a using the sensor, which was
constructed with mixed -SC6-ssDNA-10b:-S-PEG6 in
humanplasma. The LSPR-based sensor displayedΔλLSPR
of 2.9 nm in 10 nM of miR-10a solution. This value is
nearly 4.4-fold lower than ΔλLSPR observed for LSPR-
based sensor upon incubation in 10 nM of miR-10b
solution (see Figure 3A). No detectable λLSPR shift was
observed when miR-10a concentration was 1.0 pM.
This result is remarkable considering there is
only one nucleotide diﬀerence between miR-10b and
miR-10a, and that our sensor is proposed to rely on
the -ssDNA:RNA duplex formation where attachment
of miR-10b/10a to nanoprism-bound -ssDNA-10b in-
creases the local dielectric environment and modu-
lates ΔλLSPR. We believe that the 2.9 nm shift of ΔλLSPR
for 10 nM of miR-10a was not controlled by the duplex
formation between nanoprism-bound -ssDNA-10b and
miR-10a since there is only a single nucleotide diﬀer-
ence between them. This value is in agreement with
the low molecular weight of miR-10a of ∼6.9 kDa that
will only inﬂuence local dielectric environment mini-
mally, and we expect that at higher concentrations
miR-10a would attach to the sensors and inﬂuence the
LSPR properties.
Wehypothesize that due to -ssDNA-10bandmiR-10b
duplex formation, a long distance charge transport
takes place that alters the electron density and elec-
tromagnetic ﬁeld around the nanoprisms, resulting in
alteration of their LSPR properties. A long distance
charge transport through a duplex DNA backbone is
known to occur6062 where a single base pair mis-
match inﬂuences the conductivity signiﬁcantly.60,63
Therefore, we believe in the case of duplex formation
between nanoprisms bound -ssDNA-10b and miR-10a,
the delocalization of free electrons of gold nanoprisms
throughout the entire DNA helix did not take place,
as illustrated schematically in Figure 3B,C. To test
our hypothesis, we designed LSPR-based sensors by
functionalizing gold nanoprisms by -SC6-ssDNA-10a:
-S-PEG6 and determined the sensitivity using miR-10a
in human plasma where LOD was found to be an
∼75 aM (data not shown). This result is expected
because -ssDNA-10a and miR-10a form a duplex struc-
ture without any nucleotide mismatch, which would
result free electrons delocalization.
We believe that one nucleotide diﬀerence would
not alter duplex formation between -ssDNA-10b
and miR-10a, and that most of the miR-10a would
therefore be attached onto the sensor's surface, akin
to the -ssDNA-10b/miR-10b duplex. To test our hypoth-
esis, we quantiﬁed the level of unbound miR-10a in
1.0 nM solution after incubating with human plasma
the LSPR-based sensor that was constructed with
mixed -SC6-ssDNA-10b:-S-PEG6. The LSPR-based sensor
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displayed an average 2.5 nm shift ofΔλLSPR, as expected
(see Figure 3A). The miR-10a remaining in solution
was then assayed using a sensor constructed with
mixed -SC6-ssDNA-10a:-S-PEG6,which revealed an aver-
age 6.1 nm shift in the ΔλLSPR (Figure S5). On the basis
of our miR-10a calibration curve, this ΔλLSPR value
corresponds to a concentration of 1.4 104 nM, which
is∼7 103-fold lower than the original 1.0 nMmiR-10a
concentration. In parallel, we quantiﬁed the level of
unbound miR-10b in 1.0 nM solution after incubating
with human plasma the LSPR-based sensor that was
constructed with mixed -SC6-ssDNA-10b:-S-PEG6. A
5.4 nm shift ofΔλLSPR was observed, which corresponds
to a concentration of 4.3 105 nM using the equation
for the calibration curve reported in Table S2. This
value is only 3-fold lower than the value determined
for miR-10a that was free in solution after incubation
into miR-10b sensors. Thus, the vast majority of miR-10a
and miR-10b formed a duplex with the -ssDNA-10b-
based LSPR sensor, and a single nucleotide mis-
match at the 12th position did not impede miR-10a
duplex formation. Our data are in agreement with
reports in the literature indicating that single base
pair mismatch in duplex DNA does not alter the
equilibrium constant.64
Together, these results support our hypothesis of
electron delocalization processes as a predominant
factor of controlling the dramatic shift of ΔλLSPR.
To the best of our knowledge, this is the ﬁrst LSPR-
based sensing approach that is able to distinguish
betweennucleotides having a single base pairmismatch
at concentrations <10 pM, which is at least a magnitude
better than other label-free sensors.22,23,29,31,32 We are
actively working to understand possible charge trans-
port and/or electronsdelocalizationprocesses that could
result in further improvement in the sensing ability
of our LSPR-based sensors. Our experimental data
are important in the context of precise quantiﬁcation
of miR-10b that is released by PCCs into the medium or
circulation with a very low concentration as discussed
below.
Quantitative Analysis of miR-10b Levels in Cultured Pancre-
atic Cancer Cells and their Released Products. Chemotherapy
resistance occurring in conjunction with a propensity
to metastasize and a lack of early stage screening
procedures contributes to the high PDAC-related
Figure 3. (A) Comparison of miR-10b (red bars) and miR-10a (blue bars) concentration-dependent LSPR responses, which
were determined using LSPR-based sensors where gold nanoprisms were functionalized with -SC6-ssDNA-10b:-S-PEG6.
Schematic representation illustrates electron-transport through duplex DNA in LSPR-based sensor which was fabricatedwith
-SC6-ssDNA-10b:-S-PEG6 in hybridization with miR-10b (B) and miR-10a (C). The dotted circles represent broken helix
structures that hinder electron transport resulting in an attenuated LSPR response.
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mortality. It has therefore been proposed that a non-
invasive test for the early detection of PDAC could
significantly improve screening strategies and ulti-
mately lead to a vastly improved prognosis in this
treatment-recalcitrant cancer.12,6568 It has been sug-
gested thatmiR-10bmay be an ideal plasma biomarker
for PDAC,13,69 and that glypican-1 carried by exosomes
could serve as an early diagnostic marker for PDAC.70
To further explore the possibility that circulating miR-
10b could serve as a sensitive diagnostic marker
for PDAC, we sought to establish a highly sensitive
and quantitative assay for miR-10b concentrations in
various biological compartments that include PCC-
derived conditioned media, exosomes, and plasma
(Figure 1). Here, for the first time we demonstrate a
sensing approach which is able to precisely quantify
the concentration of (i) extractedmiR-10b from human
PCCs, (ii) miR-10b in Roswell Park Memorial Institute
(RPMI) medium and Dulbecco's modified Eagle's
medium (DMEM) from these cells, (iii) extracted miR-
10b from exosomes from these PCCs, and (iv) miR-10b
in exosome-free supernatants (Sup) generated following
two sequential ultracentrifugations (Sup-1 and Sup-2) as
shown in Figure 4. Our detectionmethod overcomes the
limitation of the most widely used technique, qRT-PCR,
which can only provide relative miR values rather
than actual miR concentrations and which require
RNA extraction procedures. Because the pancreatic
tumor microenvironment (TME) is hypoxic71,72 and
hypoxia up-regulates miR-10b expression,13AsPC-1,
BxPC-3, and PANC-1 cells engineered to overexpress
miR-10b were grown under normoxia and hypoxia
(1% O2) conditions. By analyzing the concentration of
miRs directly in media from the above PCCs as well
as in exosomes released by these PCCs, We were able
to investigate the proportion of miR-10b released by
PCCs directly into the culture medium by comparison
to its release via exosomes.
To quantify miR-10b levels in the above PCCs, cells
(4 105)were lysed and total RNA (includingmiRs) was
extracted using a TRIzol kit followed by a single-step
puriﬁcation with the Direct-zol RNA MiniPrep kit which
yielded a ﬁnal elution volume of 30 μL/sample. Next,
14 μL from each sample was used for LSPR-based
detection, whereas the remaining 14 μL was used for
qRT-PCR. We quantiﬁed miR-10b in crude media from
each cell line by incubating over the LSPR-based sensor
for 12 h, as described in the Materials and Methods.
Subsequently, the sensors were washed with PBS
buﬀer, and the λLSPR was measured. Figure 5AC
illustrates the LSPR-based determination of miR-10b
concentrations in two types of media from three
diﬀerent PCCs. RPMI medium that was collected from
BxPC-3 and AsPC-1 cells that were grown under hy-
poxia contained ∼462 and 360 fM of miR-10b, respec-
tively. DMEM collected from PANC-1 cells grown under
hypoxia contained ∼70 fM of miR-10b. We observed a
similar pattern for miR-10b concentrations that were
determined following extraction of total RNA from
BxPC-3, AsPC-1, and PANC-1 cells of ∼390, ∼20, and
∼5 fM, respectively. We also compared the LSPR-based
values with qRT-PCR data from the same samples and
they showed the same general trend (Figure 5DF).
To better understand the potential pathways for
miR-10b release by PCCs, we next sought to determine
the concentrations of miR-10b in exosomes, and Sup-1
and Sup-2 generated following two sequential ultra-
centrifugations ofmedia collected fromPCCs thatwere
cultured under hypoxia or normoxia conditions. Under
hypoxia, miR-10b concentrations were ∼76, ∼85,
and ∼67 fM in exosomes collected from BxPC-3,
AsPC-1, and PANC-1 cell-derived media, respectively.
Figure 4. Schematic representation of the strategy for assaying miR-10b levels in various biological compartments by qRT-
PCR and LSPR-based assay. Media from AsPC-1, BxPC-3, and PANC-1 cells, which were grown under normoxia and hypoxia
conditions, were collected (a) and miR-10b was quantiﬁed by the LSPR-based technique and by qRT-PCR. Aliquots of media
were subjected to two sequential ultracentrifugations (b) with an intervening PBS wash, and exosomes (c) and supernatant-1
(Sup-1, d) were collected separately. Sup-1 was again ultracentrifuged at 100 000g and Sup-2 (e) was collected. The LSPR-
based techniquewas used to quantifymiR-10b directly in Sup-1 and Sup-2, while qRT-PCRwas used to determine the relative
miR-10b levels after RNA extraction. No visible residue was detected after the second ultracentrifugation.
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The concentrations of miR-10b were ∼31, ∼12, and
∼8 fM in Sup-1 from BxPC-3, AsPC-1, and PANC-1
cells, respectively, and in the ∼150300 aM range
in Sup-2 (Figure 5AC). We observed a similar trend
in our qRT-PCR analysis (Figure 5DF). This is the
lowest concentration determined by any label-free miR
sensors without RNA extraction.2224,26,28,29,31,32,54 By
contrast, we were unable to quantify miR-10b levels
in sup-2 qRT-PCR. Therefore, our LSPR-based sensing
technique allows for the quantitative assay of miR-10b
in diverse physiological media without requiring miR
extraction, and is more sensitive than the widely used
qRT-PCR technique.
Using our LSPR-based technique we also deter-
mined that miR-10b levels under hypoxic conditions
in exosomes were at least 3-fold (AsPC-1 and BxPC-3
cells) and as high as 28-fold (PANC-1 cells) higher
than under normoxic conditions (Figure 5AC). We
also compared the LSPR-based concentration values
with the qRT-PCR results (from the same sample with
total RNAs extraction) and miR-10b levels exhibited
the same trend by qRT-PCR as by LSPR (Figure 5DF).
To conﬁrm that our assays measured miR-10b in exo-
somes, we obtained transmission electron microscopy
(TEM) images of the exosomes (Figure 6), which
were isolated from PANC-1 cell-derived medium. The
diameters of the exosomes were easy to determine
(∼60140 nm), even though some appeared to
be aggregated, which could be due to the drying
process during the TEM grid preparation. The detailed
procedures for exosomes collection and RNAs extrac-
tion are provided in the Materials and Methods.
Our ﬁndings thus demonstrate that miR-10b con-
centrations are elevated under hypoxic conditions in
exosomes, raising the possibility that miR-10b acts
within the hypoxic TME to promote PDAC biological
aggressiveness.
The data presented above on accurate quantiﬁca-
tion of miR-10b in various biological compartments
using our ultrasensitive LSPR-based sensor provide
insight into several important cellular processes that
contribute to the release of miRs by PCCs in circulation.
First, under hypoxia, miR-10b concentrations deter-
mined in exosomes collected from diﬀerent cell lines
were found to be comparable, and as high as 85 fM
in ASPC-1 cells. Thus, PCCs release miR-10b rich exo-
somes into conditioned media, raising the possibility
that it will be feasible to assay exosomal miRs as
potential biomarkers of PDAC. Second, the concentra-
tions of miR-10b in Sup-1 and Sup-2 were in the
femtomolar and attomolar range in all three-cell lines.
Therefore, some residual miRs were still present in
the supernatant collected from media even after
two sequential ultracentrifugations with intervening
Figure 5. (AC) Determination of miR-10b concentrations in three diﬀerent pancreatic cancer cell lines under two diﬀerent
culture conditions, normoxia (blue bars) and hypoxia (red bars), in various biological compartments using our LSPR-based
sensors. Determination of miR-10b concentrations in media, Sup-1, and Sup-2 was performed without RNA extraction,
whereas total RNAwas extracted from cells and exosomes. All three cell lineswere engineered to overexpressmiR-10b. (DF)
qRT-PCR values for normoxia (purple bars) and hypoxia (green bars) using sham-transfected pancreatic cancer cells and cells
engineered to overexpress miR-10b (blue and red bars). miR-10b was assayed in total RNA extracted from media, cell,
exosomes, and Sup-1 under normoxia (blue bars) and hypoxia conditions (red bars). The LSPR-based concentration and qRT-
PCR fold change inmiR-10b levels in cells and exosomeswere determined fromaliquots derived from the corresponding total
RNA samples. However, by qRT-PCR,miR-10bwas not detectable in Sup-2. The detailed procedure for exosomes isolation and
RNAs extraction procedure are provided in the Materials and Methods.
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washing with PBS. The presence of miR-10b in Sup-1
and Sup-2 suggests that in addition to being released
via exosomes, miRs are released directly by PCCs into
their environment. Although the speciﬁc cellular path-
ways for miR-10b release remain to be delineated, it is
conceivable that miR-10b could detach from Ago2
proteinmiR complexes as byproducts of dead cells,
or be released due to the rupturing of exosomes or
microvesicles because of high mechanical force ap-
plied during ultracentrifugation.73,74 The miR-10 con-
centrations in exosomes were at least 15% (BxPC-3
cells) and as high as 84% (PANC-1 cells) of total
extracellular miR-10b levels (media, Sup-1 and Sup-2).
Overall, we have performed the ﬁrst comprehensive
determination of miR concentrations at the attomolar
range in various PCCs, under various growth condi-
tions, and in diﬀerent biological compartments. Our
investigation has signiﬁcant implications for the devel-
opment of biomarkers for the early diagnosis of PDAC
through isolation and quantiﬁcation of circulating
miR-10b, as discussed in the next section, as well as
for the diagnosis of other cancers in which circulating
miRs are elevated.
Exosome miR-10b Levels in Patients with Pancreatic Cancer
and Chronic Pancreatitis. Although hundreds of human
miRs are known, their exact role in various aspects of
cancer progression and modulation of cell prolifera-
tion, apoptosis, and metastasis is yet to be delineated.
Importantly, these small, noncoding RNAs have the
potential to serve as diagnostic markers for different
diseases including PDAC. Plasma miR-10b levels, as
determined by qRT-PCR, are elevated in PDAC patients
by comparison with CP patients and normal control
subjects or patients with gall-bladder disease.13,69
However, PCR-based assays require RNA extraction
and purification, are only semiquantitative, and are
not sufficiently sensitive to differentiate miR-10b levels
in patients with CP from levels in normal controls.13 As
demonstrated above, our label-free, LSPR-based detec-
tion technique is able to assay attomolar concentra-
tions of miR-10b directly not only in conditioned
media, but also in PCC-derived exosomes. Therefore,
it would be a breakthrough to establish an analytical
technique that could be used to detect and quantify
miR-10b directly in crude plasma samples.
Here, we report as a proof of principle, the ﬁrst
label-free assay to quantify and compare the miR
levels between patients with PDAC (n = 3), CP (n = 3),
and normal controls (n = 3). Moreover, we determined
the concentration of miR-10b in crude plasma, exo-
somes, and Sup-1 and Sup-2. The exosomes were
collected from plasma through ultracentrifugation as
described in the Materials and Methods. Figure 7A
illustrates the TEM image of exosomes collected from
plasma of a PDAC patient. A brief TRIzol extraction,
followed by a single-step puriﬁcation using the direct-
zol RNA MiniPrep kit makes our assay simple and
innovative.
Figure 6. TEM images of exosomes collected from miR-10b overexpressing PANC-1 cells. A 10 μL solution was drop-casted
onto a formvar-coated copper grid and allowed to stand for 60 s. Excess solution was wicked away with a ﬁlter paper. A 2.0%
uranyl acetate solution was applied for 10 s to negatively stain the exosomes. Scale bars: 100 nm.
Figure 7. (A) A representative TEM image showing exo-
somes of ∼50120 nm in diameter. Plasma from a patient
with PDAC (500 μL) was ultracentrifuged twice, the pellets
were suspended in 100 μL of 2% glutaraldehyde/2% para-
formaldehyde solution, and a 10 μL aliquotwas drop-casted
onto a formvar-coated copper grid. The solution was al-
lowed to stand for 60 s, and excess solution was wicked
away with a ﬁlter paper. A 2.0% uranyl acetate solution was
applied for 10 s to negatively stain the exosomes. Scale bar:
100 nm. (B) Immunoblotting of plasma-derived exosomes
and plasma validates ultracentrifugation method. Plasma
samples from two PDAC patients (500 μL/sample) were
cleared of cellular debris by centrifugation at 10 000g
(4 C) for 30 min. Supernatants were transferred to a new
tube and subjected to ultracentrifugation at 100 000g for
70 min (4 C). The exosome pellets (lanes 1 and 2) were
washed with PBS and subjected to a second ultracentrifuga-
tion. Pellets were then suspended in 40 μL of protein lysis
buﬀer as previously described.69 The corresponding exosome-
depleted plasma (50 μL/sample) aliquots (lanes 3 and 4)
were also subjected to immunoblotting following addition
of an equal volume of 2 lysis buﬀer. Samples (20 μL each;
1 μg/μL) were loaded on a 10% acrylamide gel and
immunoblotting was performed using anti-Alix, anti-Tsg101,
and anti-CA19-9 antibodies.69
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Exosomes are of endosomal origin and therefore
express endosomal proteins such as tumor suscept-
ibility gene 101 (Tsg101) and Alix.15 Exosomes that
are of PDAC origin are also expected to express
carbohydrate-associated 19-9 (CA19-9), which is a
well-known pancreatic tumor marker in the circula-
tion.75 To conﬁrm that our plasma ultracentrifugation
procedures yielded PDAC-derived exosomes, lysates
of freshly isolated exosomes (20 μg/sample) and 50 μL
of plasma supernatants were subjected to immuno-
blotting for TSG1, Alix, and CA19-9 (Figure 7B). Our data
show that plasma exosomes from PDAC patients ex-
press Alix, Tsg101, and CA19-9, and that neither Alix
nor Tsg101 is present in the plasma following the initial
ultracentrifugation (Figure 7B). By contrast, CA19-9, as
expected, is present in exosome-depleted plasma.
The concentrations of miR-10b in diﬀerent bio-
logical compartments were determined using our
LSPR-based assay, as shown in Figure 8AC. All three
samples from PDAC patients exhibited high levels
of miR-10b in both plasma and circulating exosomes
(Figure 8B). By contrast, the same LSPR-based assay
revealed that miR-10b levels in plasma and exosomes
from normal controls (Figure 8A) and CP patients
(Figure 8C) were 50- to 60-fold lower and 4- to 10-fold
lower, respectively, than those in the corresponding
PDAC samples. Importantly, miR-10b levels in the
CP samples (Figure 8C) were signiﬁcantly higher than
Figure 8. (AC) Determination of miR-10b concentration in plasma samples from three normal control (NC), three patients
with PDAC, and three patients with CP using our LSPR-based sensors. Determination of miR-10b levels in plasma, Sup-1, and
Sup-2 was performed without RNA extraction, whereas total RNA was extracted from exosomes. (DF) qRT-PCR values for
miR-10b from total RNA extracted from exosomes and Sup-1 in three NC, three patients with PDAC, and three patients with
CP. The LSPR-based concentration and qRT-PCR values for miR-10b in exosomes were determined from the same RNA
samples from each subject, all performed in a blindedmanner. Each color represents a diﬀerent PDAC, CP, or control subject.
MiR-10b levels in Sup-2 were below the level of detection by qRT-PCR and, hence, are not shown.
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those in normal controls (Figure 8A). Figure 8DF
shows the relative miR-10b levels determined by
qRT-PCR. Supporting Information Table S7 provides
the p-values for the statistical analysis that was per-
formed to compare PDAC, CP, and normal controls.
Thus, our LSPR-based assay indicates that there are
very high levels of miR-10b in the exosomes isolated
from the plasma of PDAC patients (Figure 8), which is in
contrast to observations in plasma from breast cancer
patients where only 5% of miR-16, miR-21, and miR-24
were in the exosome compartment.73 Taken together,
our data validate our hypothesis that PCCs are prone to
release miR-10b as cargo within exosomes.
Comparing our LSPR- and qRT-PCR-based data,
we can draw several conclusions regarding our unique
label-free technique. First, the trend of LSPR-based
miR-10b concentration in exosomes and Sup-1 of three
PDAC, three CP, and three normal control samples is
identical to the well-established andmost widely used,
qRT-PCR technique, underscoring the reliability of our
nanoprism-based detection technique. Second, miR-
10b levels in PDAC and CP samples were quantiﬁed
directly in patient plasma, which cannot be accom-
plished by qRT-PCR. Third, the LSPR-based assay was
able to quantify miR-10b level in Sup-2, but we were
unable to extract suﬃcient RNAs from Sup-2 for quan-
tiﬁcation by qRT-PCR. This is because the LSPR-based
technique did not require any RNA extraction method,
and is able to detect miR-10b in the subattomolar
concentration range. Fourth, while qRT-PCR fails to
diﬀerentiate between miR-10b levels in patients with
CP by comparison with normal controls (see Figure 8),
the ultrasensitive LSPR-based sensor shows that plasma
miR-10b levels are signiﬁcantly higher in CP patients
when compared to levels in normal controls. Moreover,
there was at least a 5-fold increase in miR-10b levels
in either plasma or exosomes in patients with CP when
compared with normal controls. Thus, our LSPR-based
detection technique displays unique aspects of modern
analytical methodology that allows us to precisely quan-
tify miRs at very low concentrations which is not feasible
with any other known techniques.
CP is a chronic inﬂammatory condition of the
pancreas associated with variable degrees of ﬁbrosis
which can lead to signiﬁcant pancreatic exocrine
and endocrine dysfunction, glucose intolerance, and
diabetes.76 Although most patients with CP do not
develop PDAC, it is well established that CP is asso-
ciated with a higher risk for developing PDAC.77 How-
ever, there are no markers that will help stratify CP
patients with respect to their risk for developing PDAC.
Our observations that CP patients exhibit slight
but signiﬁcant increases in miR-10b levels in both the
plasma and circulating exosomes by comparison with
normal controls raise the possibility that monitoring
for rising miR-10b levels in CP patients by using our
ultrasensitive LSPR-based sensor could identify those
patients that are at a high risk for developing PDAC
and that need further evaluation by procedures such as
endoscopic ultrasonography, thereby allowing for the
early detection of CP progression to PDAC.
Our LSPR-based quantiﬁcation showed that miR-
10b is present at high concentrations (∼210 fM) in
exosomes isolated from the plasma of PDAC patients,
whereas the supernatants post-centrifugation (Sup-1,
∼1050 fM; and Sup-2, 70300 aM) had exceedingly
low miR-10b levels. Therefore, the vast majority of
miR-10b that is released by PCCs is present in the
exosomes. Importantly, analysis of the TCGA data for
PDAC revealed that many of the PDAC tissue samples
in TCGA exhibit increasedmiR-10b expression, ranging
as high as∼180 000 reads per million (RPM). Moreover,
there are ﬁve Stage IA and eight stage IB PDAC cases
in the TCGA data, with mean miR-10b values of 13 400
and 15 225 RPM, respectively, indicating that miR-10b
is already elevated at the earliest stages of clinical
presentation for PDAC. Our simple, label-free, highly
speciﬁc, and regenerative LSPR-based sensors would
thus allow for quantitative measurements of miR-10b
circulating in exosomes, which could serve as a bio-
marker for early PDAC diagnosis. Importantly, the work-
ing principle of our LSPR-based sensor is that the
attachment of miR-10b to nanoprism-bound -ssDNA-
10b increases the local dielectric environment and
modulates ΔλLSPR. Therefore, modifying the surface
of the nanoprisms by any type of -ssDNA would allow
for the quantitative detection of any complementary
miR-X (for example, X = 30c, 106b, 155, and 212) that is
overexpressed in PDAC.13 We believe that our ultrasen-
sitive assay will allow for the detection in plasma of miRs
that are under-expressed in PDAC and other pathologi-
cal conditions, and we have initiated the development
of additional LSPR-based sensors that could quantify
miR-X level, including those with single nucleotide
speciﬁcity, in biological ﬂuids and exosomes.
CONCLUSION
In conclusion, we have demonstrated a simple and
novel ultrasensitive LSPR-based sensing platform that
enables a quantitative determination of miR-10b in
biological ﬂuids and exosomeswith a single nucleotide
speciﬁcity at the attomolar concentration. We believe
that the high sensitivity of our LSPR-based sensor is
due to charge transport and/or delocalization of free
electrons of the gold nanoprisms through DNA back-
bone when ssDNA forms the duplex and becomes
double-stranded. Our label-free LSPR-based detection
technique provides a unique opportunity for bypass-
ing current detection approaches that require compli-
cated fabrication methods or extra-labeling, and that
fail to work in complex biological ﬂuids. Moreover, our
LSPR-based sensor is regenerative through multiple
cycles and stable for at least 5 days without diminu-
tion in sensitivity. The LSPR-based assay has also
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demonstrated that miR-10b release via exosomes by
PCCs is greatly enhanced under hypoxic conditions.
We have also shown the versatility of our detection
technique through precise quantiﬁcation of miR-10b
without any RNA extraction method in plasma of
patients with PDAC and CP, and reliably diﬀerentiate
between patients with CP and normal controls. To the
best of our knowledge, this is the ﬁrst demonstration of
a label-free technique to quantify miRs in exosomes
and the ﬁrst report to show that miR-10b is abundant
in circulating exosomes in PDAC patients. Future stud-
ies are required to validate the diagnostic accuracy of
this technique in larger cohorts. We believe that our
novel sensing platform, which enables quantiﬁcation
of attomolar concentrations of miR biomarkers from
biological ﬂuids without requiring extensive sample
preparation, may also have prognostic and therapeutic
implications.
MATERIALS AND METHODS
Materials. Chloro(triethylphosphine) gold(I) (Et3PAuCl, 97%),
poly(methylhydrosiloxane) (PMHS, Mn = 17003300), triocty-
lamine (TOA, 98%), ACS grade acetonitrile (CH3CN, 99.9%),
methanol (99.8%), human plasma (contains 4% trisodium citrate
and tested for HIV, hepatitis C and hepatitis B), thiol modified
ssDNAs, microRNAs (miRs), Tris-base, magnesium chloride
(MgCl2), and potassium chloride (KCl) were purchased from
Sigma-Aldrich and were used as received. (3-Mercaptopropyl)-
triethoxysilane (MPTES, 94%) was purchased fromAlfa Aesar, and
ethanol (alcohol 200 proof) was purchased from Decon labs.
RNase H enzyme and RNase H reaction buffer were purchased
from New England Bio Labs, Inc. RNase-free sterile water was
obtained from Baxter Healthcare Corporation. 1, 4-Dithiothreitol
(DTT) was purchased from Roche Diagnostics. Anti-Alix (1:1000
dilution) was from Sigma, anti-Tsg101 (1:200 dilution) from Santa
Cruz, and anti-CA19-9 (1:200 dilution) from Abcam. Hydrochloric
acid (HCl), sodium chloride (NaCl, g99.5%), sodium phosphate
monobasic monohydrate (NaH2PO4.H2O, >98%), sodium phos-
phate dibasic anhydrous (Na2HPO4), and the glass coverslipswere
purchased from Fisher Scientific. RBS 35 Detergent was obtained
from Thermo Scientific and used as received. The super Sharpe
silicon scanning probes (SSS-NCHR) for atomic force microscopy
measurements were purchased from nanosensors. All water
was purified using a Thermo Scientific Barnstead Nanopure
system. Thiol modified oligonucleotides and all miRs were stored
at 20 C. RNase-free sterile water was used to prepare the PBS
buffer solution. Polyethylene glycol thiol (PEG6-SH) was synthe-
sized in our laboratory using published procedures.78 TRIzol and
TRIzol LS were purchased from Life Technologies. Direct-zol RNA
MiniPrep kit was purchased from Zymo Research.
Synthesis of Gold Nanoprisms with Various Edge Lengths. Gold
nanoprisms were chemically synthesized according to our
previously developed procedure with minor modification.59,79
Specifically, Et3PAu(I)Cl (8mg, 0.02mmol) was dissolved in 5mL
of acetonitrile and allowed to stir for 5min at room temperature
in an Erlenmeyer flask. A total of 0.085 mL of TOA and 0.3 mL
of PMHS were mixed with 1 mL of acetonitrile in a vial and
injected into the above solution. The reaction mixture was then
allowed to heat at 40 C. The solution color started to change
from colorless to pink, purple, blue, and at this point, 14 mL
of acetonitrile was added to the reaction and the reaction was
allowed to run for another 60 min, which resulted in a dark blue
solution indicating the formation of nanoprisms with a stable
localized surface plasmon resonance dipole peak (λLSPR) at
750 nm in acetonitrile (Figure S1 and Table S2). At this point,
the solution was removed from heat, centrifuged at 7000 rpm
for 2 min, and used to fabricate LSPR-based sensors. The SEM
analysis confirmed an average edge-length of 34 nm. Gold
nanoprisms with an average 42 nm (λLSPR = 800 nm) and 47 nm
(λLSPR = 820 nm) edge-length were synthesized using identical
mole ratio of Et3PAuCl and PMHS, but changing the TOA
amount of 0.095 and 0.1 mL, respectively.
Fabrication of LSPR-Based miR-10b Sensors. The gold nanoprisms
containing LSPR-based sensors for miR-10b detection were
developed using our published method.45 A tape cleaning pro-
cedure was carried out, in order to remove the nonprismatic
nanostructures from the coverslips. Adhesive tape was applied
to the gold nanoprisms-bound substrate surface, gently pressed
down with a finger, and then slowly removed at a 90 angle.
The nanoprisms-bound substrates were subjected to overnight
incubation in a solution of PBS that contained a 1:1 ratio of 1.0 μM
solution of HS-C6-ssDNA-10b and HS-PEG6. Finally, the -S-C6-
ssDNA-10b and -S-PEG6 functionalized nanoprisms were rinsed
with adequate amount of PBS buffer solution to remove non-
specifically bound thiols. These functionalized nanoprisms, which
were covalently attached onto supporting substrate and denoted
as the LSPR-based sensor, were further utilized for miR-10b
detection. We obtained the concentration of miR-10b in each
media from the observed λLSPR shift and converted it into the
corresponding concentration using the calibration curve derived
formiR-10bunder various conditions,which include twodifferent
physiological media (human plasma and PBS buffer), two dif-
ferent culture media (RPMI and DMEM) and two different growth
conditions (normoxia and hypoxia) (see Supporting Information
Figure S4 and Table S3).
Cell Culture. Stably overexpressing miR-10b and control
ASPC-1, BxPC-3, and PANC-1 cells from ATCC (Manassas, VA)
were grown in culture at 37 C, 5% CO2 in either RPMI 1640
(AsPC-1 and BxPC-3) or DMEM (PANC-1) with 5% FBS (exosomes
depleted) and 1% penicillin/streptomycin as described pre-
viously by our group.69 Cells were plated in 60 mm dishes at
a concentration of 4  105 and grown in standard conditions
(normoxia) for 72 h. For hypoxic conditions, plates were re-
moved from normoxia at 24 h post-plating and transferred to
a hypoxia chamber at 37 C, 5% CO2, and 1% O2 for 48 h.
Engineered miR-10b PCCs and RNA Isolation. Cells were stably
transduced to overexpress miR-10b with the MDH1-PGK-GFP
microRNA-10b retroviral construct (Addgene plasmid 16070)
with packaging plasmids PAX2 and pMD2.G. Sham-transfections
to generate control cells were established by transduction with
an empty MDH1-PGK-GFP construct (Addgene plasmid 11375)
using Phoenix cells for retroviral packaging (Life Technologies).
Harvested viruses were used for transduction as previously
described,80 and GFP-positive cells were isolated using flow
cytometry 48 h post-transduction (Flow Cytometry Facility, In-
dianaUniversity School ofMedicine, Indianapolis, IN, USA). Sorted
cells were plated and cultured as described above and allowed
to recover for 48 h prior to use in experiments. Validation of
continuedmiR-10b overexpressionwas confirmed bymonitoring
GFP fluorescence and miR-10b levels by qRT-PCR. RNA was iso-
lated from cells using TRIzol, or from media using TRIzol LS
according to manufacturer's protocol.
Exosome Isolation from Plasma and RNA Isolation. Plasma samples
from PDAC, CP, and normal controls (500 μL/sample) were
centrifuged at 10 000g (4 C) for 30 min. Supernatants were
transferred to a new tube and subjected to ultracentrifugation
at 100 000g for 70 min (4 C). The supernatant was removed to
a new tube for analysis, the pellet was the washed with 1 PBS,
and ultracentrifugation was repeated. RNA isolation (100 μL/
plasma sample) was performed using the TRIzol kit followed by
a single-step purification with the Direct-zol RNA MiniPrep kit
(Zymo Research).
LSPR-Based Quantification of Plasma and Exosomal miR-10b. Plasma
(100 μL) from either PDAC or CP patients was diluted with 2.5 mL
of PBS buffer. The LSPR-based sensors were incubated over-
night and then rinsed with PBS buffer, and extinction spectra
were collected in PBS buffer to quantify the miR-10b levels.
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For exosomal miR-10b quantification, 20 μL of the TRIzol isolate
was subjected to a single-step purification procedurewith Direct-
zol, and the sample was diluted with 2.0 mL of PBS buffer and
incubated overnight with LSPR-based sensors. In this case, the
extinction spectra were collected in PBS buffer. For accurate
quantification of miR-10b in each compartment, each PDAC, CP,
and normal control sample was assayed twice using a total of
10 sensors.
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